HeartBeam reported financial and operational results for the fourth quarter and full year ended December 31, 2025, highlighting significant progress toward commercialization following U.S. Food and Drug Administration 510(k) clearance of its 12-lead electrocardiogram synthesis software in December 2025. The company has initiated a limited market launch targeting concierge and preventive cardiology groups and secured its first commercial partnership with ClearCardio, while also enrolling initial patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection.
The importance of this development lies in HeartBeam's creation of the first-ever cable-free device capable of collecting ECG signals in three dimensions from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities, potentially redefining cardiac health management.
Additional developments include completion of a prototype extended-wear 12-lead ECG patch, a strategic collaboration with the Icahn School of Medicine at Mount Sinai to advance AI-enabled ECG algorithms, and the appointment of a new chief commercial officer to support growth initiatives. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement.
The implications of this announcement are substantial for cardiac care delivery. By enabling 12-lead ECG monitoring outside traditional medical settings, HeartBeam's technology could significantly improve early detection of heart attacks and other cardiac events, potentially reducing treatment delays and improving patient outcomes. The technology's portability addresses a critical gap in current cardiac monitoring systems, which typically require patients to be in clinical settings for comprehensive ECG analysis.
For the healthcare industry, HeartBeam's progress represents a shift toward more accessible, patient-centered cardiac monitoring. The collaboration with Mount Sinai's Icahn School of Medicine to develop AI-enabled ECG algorithms suggests future enhancements that could further improve diagnostic accuracy and efficiency. The limited market launch with concierge and preventive cardiology groups indicates an initial focus on high-value applications where early detection is most critical.
Investors and industry observers can find additional information in the company's newsroom at https://ibn.fm/BEAT. The company's forward-looking statements are subject to various risks and uncertainties detailed in SEC filings, including factors beyond management's control that may affect actual results. All parties undertake no duty to update this information unless required by law, as noted in the full terms of use and disclaimers available at http://IBN.fm/Disclaimer.
